Skip to main content
. 2012 Oct 24;12:268. doi: 10.1186/1471-2334-12-268

Table 5.

Characteristics of culture positive patients with HAP and VAP with regard to the adequacy of empirical antibiotic treatment

Characteristics
 
HAP (n = 94)
 
 
VAP (n = 117)
 
  Adequate treatment n = 43 (%) Inadequate treatment n = 51 (%) p Adequate treatment n = 37 (%) Inadequate treatment n = 80 (%) p
Age (years)
60.67 ± 16.04
65.14 ± 13.75
0.167
63.59 ± 16.65
63.85 ± 17.07
0.907
Sex (male)
32(74.4)
37 (72.5)
1.000
24 (64.9)
45 (56.3)
0.497
Surgical unit
9 (20.9)
8 (15.7)
0.697
21 (56.8)
25 (31.3)
0.015
Underlying diseases
 
 
 
 
 
 
 Diabetes mellitus
5 (11.6)
8 (15.7)
0.789
5 (13.5)
11 (13.8)
1.000
 COPD
13 ( 30.2)
10 (19.6)
0.341
11 (29.7)
17 (21.3)
0.443
 Chronic renal failure
5 (11.6)
4 (7.8)
0.727
0 (0)
3 (3.8)
0.551
 Congestive heart failure
4 (9.3)
9 (17.6)
0.386
6 (16.2)
13 (16.3)
1.000
 Cerebrovascular disease
1 (2.3)
9 (17.6)
0.019
3 (8.1)
15 (18.8)
0.227
 Malignancy
6 (14.0)
9 (17.6)
0.838
6 (16.2)
11 (13.8)
0.944
Central venous catheterization
16 (37.2)
22 (43.1)
0.710
30 (81.1)
58 (72.5)
0.442
Urinary catheterization
33 (76.7)
37 (72.5)
0.820
37 (100)
78 (97.5)
1.000
Late-onset pneumonia
34 (79.1)
46 (90.2)
0.223
34 (91.9)
72 (90)
1.000
Acquisition of other site infection
12 (27.9)
11 (21.6)
0.637
11 (29.7)
42 (52.5)
0.036
Previous antibiotic usage
20 (46.5)
23 (45.1)
1.000
11 (29.7)
36 (45.0)
0.173
MDR bacteria
29 (67.4)
38 (74.5)
0.599
32 (86.5)
60 (75)
0.243
Polymicrobial etiology
1 (2.3)
8 (15.7)
0.036
2 (5.4)
6 (7.5)
1.000
Length of stay before HAP
7.6 ± 4.3
9.18 ± 5.8
0.194
13.89 ± 11.56
14.88 ± 10.34
0.313
APACHE II score
12.7 ± 5.83
14.92 ± 5.83
0.031
16.08 ± 6.94
16.69 ± 6.72
0.654
Exitus 16 (37.2) 24 (47.1) 0.452 27 (73) 53 (66.3) 0.608